Elliot S. Vesell All publications ( 54 ) Berlin CM. Paul IM. Vesell ES. Safety issues of maternal drug therapy during breastfeeding. 2009 Jan. Clin Pharmacol Ther. 85(1):20-2. Vesell ES. Recollections from the Kunkel laboratory, 1956-1958. 2003. Lupus. 12(3):238-41. Vesell ES. Advances in pharmacogenetics and pharmacogenomics. 2000 Sep. J Clin Pharmacol. 40(9):930-8. Vesell ES. Introduction 2000 Sep. Pharmacology. 61(3):118-23. Vesell ES. Beyer KH. Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. 2000 Apr 3. Toxicology. 144(1-3):5-11. Vesell ES. Beyer KH. Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects. 1999 Mar. Pharmacology. 58(3):140-6. Vesell ES. Korsunsky Z. Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone. 1998 May. Pharmacology. 56(5):262-6. Ahsan N. Korsunsky Z. Beyer KH. Vesell ES. Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study. 1998 Aug. Pharmacology. 57(2):96-103. Follansbee MH. Beyer KH. Vesell ES. Studies on pyrazinoylguanidine. 6. Prevention of cataracts in STZ-diabetic rats. 1997 May. Pharmacology. 54(5):256-60. Follansbee MH. Beyer KH. Griffith JW. Vesell ES. Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats. 1997 May. Pharmacology. 54(5):241-55. A-Rahim YI. Rannels SL. Kimball SR. Beyer KH. Vesell ES. Studies on pyrazinoylguanidine. 4. Upregulation of phosphodiesterase activity in rat adipose tissue and downregulation of gluconeogenesis and adenosine 3',5'-monophosphate concentrations in perfused rat liver. 1996 Oct. Pharmacology. 53(4):211-8. A-Rahim YI. Beyer KH. Vesell ES. Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes. 1996 Oct. Pharmacology. 53(4):197-210. Vesell ES. Reflections from distant cuvettes. 1996 Nov. Drug Metab Rev. 28(4):493-511. A-Rahim YI. Beyer KH. Vesell ES. Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats. 1996 Mar. Pharmacology. 52(3):145-52. A-Rahim YI. Beyer KH. Vesell ES. Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats. 1996 Mar. Pharmacology. 52(3):135-44. Vesell ES. Seaton TD. A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. 1995 Feb. Pharmacogenetics. 5(1):53-7. Vesell ES. Gaylor DW. Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods. 1995 Feb. Pharmacogenetics. 5(1):18-23. Vesell ES. Chambers CE. Seaton TD. Passananti GT. Demers LM. Beyer KH. Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients. 1994 Dec. J Clin Pharmacol. 34(12):1234-45. Estévez F. De Angelo T. Vesell ES. Basal and paracetamol-depleted glutathione from human lymphocytes: ethnic variability. 1994. Acta Physiol Pharmacol Ther Latinoam. 44(1-2):48-54. Seaton MJ. Kyerematen GA. Vesell ES. Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile. 1993 Sep-Oct. Drug Metab Dispos. 21(5):927-32. Vesell ES. Chambers CE. Passananti GT. Demers LM. Beyer KH. Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus. 1993 Sep. J Clin Pharmacol. 33(9):823-31. Seaton MJ. Vesell ES. Luo H. Hawes EM. Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates using high-performance liquid chromatography. 1993 Nov 17. J Chromatogr. 621(1):49-53. Beyer KH. Ward TD. Vary JE. Gelarden RT. Knutson DW. Vesell ES. Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency. 1993 Jun. J Clin Pharmacol. 33(6):554-61. Seaton MJ. Vesell ES. Variables affecting nicotine metabolism. 1993 Dec. Pharmacol Ther. 60(3):461-500. Vesell ES. DeAngelo TM. Katz IR. Reproducibility of antipyrine half-lives in elderly subjects. 1993 Aug. Clin Pharmacol Ther. 54(2):150-7. National Institute of Mental Health Miele ME. Vesell ES. Ehmann WC. Lipton A. Harvey H. Kan NC. Hormonal and immunological regulation of 2', 5'-oligoadenylate synthetase activity in human peripheral blood mononuclear cells. 1992 Nov. Clin Immunol Immunopathol. 65(2):183-92. National Institute of Allergy and Infectious Diseases Houck JR. Romano PJ. Bartholomew M. Smith PJ. Kloszewski F. Vesell ES. Do histocompatibility antigens influence the risk of head and neck carcinoma? 1992 May 1. Cancer. 69(9):2327-32. Chambers CE. Vesell ES. Helm C. Passananti GT. Beyer KH. Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects. 1992 Dec. J Clin Pharmacol. 32(12):1128-34. Beyer KH. Gelarden RT. Vesell ES. Inhibition of urea transport across renal tubules by pyrazinoylguanidine and analogs. 1992. Pharmacology. 44(3):124-38. Passananti GT. Vesell ES. Jeszenka EV. Gelarden RT. Beyer KH. Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogs. 1992. Pharmacology. 45(3):129-41. Seaton M. Kyerematen GA. Morgan M. Jeszenka EV. Vesell ES. Nicotine metabolism in stumptailed macaques, Macaca arctoides. 1991 Sep-Oct. Drug Metab Dispos. 19(5):946-54. Vesell ES. The model drug approach in clinical pharmacology. 1991 Sep. Clin Pharmacol Ther. 50(3):239-48. Romano PJ. Bartholomew M. Smith PJ. Kloszewski F. Stryker J. Houck J. Vesell ES. HLA antigens influence resistance to lung carcinoma. 1991 Aug. Hum Immunol. 31(4):236-40. Vesell ES. Genetic and environmental factors causing variation in drug response. 1991 Apr. Mutat Res. 247(2):241-57. Kyerematen GA. Vesell ES. Metabolism of nicotine. 1991. Drug Metab Rev. 23(1-2):3-41. Vesell ES. Genetic factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes. 1991. Ann Genet. 34(3-4):167-72. Kyerematen GA. Morgan M. Warner G. Martin LF. Vesell ES. Metabolism of nicotine by hepatocytes. 1990 Oct 15. Biochem Pharmacol. 40(8):1747-56. Beyer KH. Gelarden RT. Vary JE. Brown LE. Vesell ES. Novel multivalent effects of pyrazinoylguanidine in patients with azotemia. 1990 May. Clin Pharmacol Ther. 47(5):629-38. Passananti GT. Wolff CA. Vesell ES. Reproducibility of individual rates of ethanol metabolism in fasting subjects. 1990 Mar. Clin Pharmacol Ther. 47(3):389-96. Kyerematen GA. Morgan ML. Chattopadhyay B. deBethizy JD. Vesell ES. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. 1990 Dec. Clin Pharmacol Ther. 48(6):641-51. National Institute of General Medical Sciences National Center for Research Resources Vickers FF. Bowman TA. Dvorchik BH. Passananti GT. Hughes DM. Vesell ES. On the antipyrine test in laboratory animals. Studies in the dog and monkey. 1989 Mar-Apr. Drug Metab Dispos. 17(2):160-5. Denlinger CL. Vesell ES. Hormonal regulation of the developmental pattern of epoxide hydrolases. Studies in rat liver. 1989 Feb 15. Biochem Pharmacol. 38(4):603-10. Norris KK. DeAngelo TM. Vesell ES. Genetic and environmental factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes. 1989 Dec. J Clin Invest. 84(6):1749-56. Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. 1989. Pharmacol Ther. 41(3):535-52. Vesell ES. Heubel F. Netter KJ. Brief maternal deprivation of rats reduces hepatic mixed function oxidase activities. 1989. Life Sci. 45(19):1755-61. Kyerematen GA. Owens GF. Chattopadhyay B. deBethizy JD. Vesell ES. Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. 1988 Nov-Dec. Drug Metab Dispos. 16(6):823-8. National Institute of General Medical Sciences Kyerematen GA. Taylor LH. deBethizy JD. Vesell ES. Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. 1988 Jan-Feb. Drug Metab Dispos. 16(1):125-9. National Institute of General Medical Sciences Fabisiak JP. Vesell ES. Rannels DE. Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. I. Analysis, characterization and regulation of specific beta adrenergic receptors. 1987 May. J Pharmacol Exp Ther. 241(2):722-7. National Heart, Lung, and Blood Institute Fabisiak JP. Vesell ES. Rannels DE. Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. II. Receptor-independent accumulation of beta adrenergic antagonists and other cationic amphiphilic drugs in lamellar bodies. 1987 May. J Pharmacol Exp Ther. 241(2):728-35. National Heart, Lung, and Blood Institute Kyerematen GA. Taylor LH. deBethizy JD. Vesell ES. Radiometric-high-performance liquid chromatographic assay for nicotine and twelve of its metabolites. 1987 Aug 7. J Chromatogr. 419:191-203. National Institute of General Medical Sciences National Center for Research Resources Vesell ES. Pharmacogenetic perspectives on susceptibility to toxic industrial chemicals. 1987 Aug. Br J Ind Med. 44(8):505-9. Fabisiak JP. Rannels SR. Vesell ES. Rannels DE. Receptor-independent sequestration of beta-adrenergic ligands by alveolar type II cells. 1986 Jun. Am J Physiol. 250(6 Pt 1):C871-9. National Heart, Lung, and Blood Institute Hartshorn RD. Demers LM. Sultatos LG. Vesell ES. Lang CM. Hughes HC. Effects of chronic parenteral carbohydrate administration on hepatic drug metabolism in the rat. 1979. Pharmacology. 18(2):103-11. Hepner GW. Vesell ES. Lipton A. Harvey HA. Wilkinson GR. Schenker S. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. 1977 Sep. J Lab Clin Med. 90(3):440-56.